This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DOXIL
Gynecologic cancers
Kaposi's sarcoma
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DOXIL Rx

Generic Name and Formulations:
Doxorubicin HCl (liposomal) 2mg/mL; dispersion for IV infusion after dilution; preservative-free.

Company:
Janssen Biotech, Inc.

Therapeutic Use:

Indications for DOXIL:

Ovarian cancer refractory to platinum-based chemotherapy.

Adult:

Give by IV infusion at initial rate of 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur; may premedicate with antiemetics. 50mg/m2 once every 4 weeks; continue for at least 4 cycles as tolerated. Hepatic dysfunction (serum bilirubin ≥1.2mg/dL), hand-foot syndrome, hematologic toxicity (esp. ANC, platelets), or stomatitis: reduce dose. Consider total anthracycline and anthracenedione doses and irradiation when calculating total cumulative dose. See full labeling.

Children:

Not established.

Warnings/Precautions:

Not substitutable on a mg/mg basis with other doxorubicin products. Cardiomyopathy (including left ventricular failure), acute infusion-related reactions, myelosuppression may occur. Have medications to treat infusion-related reactions and resuscitative equipment available. Hepatic impairment. Monitor blood (esp. CBC + platelets), hepatic (esp. SGOT/SGPT, alkaline phosphatase), and cardiac function (eg, MUGA, ECG). Monitor periodically for secondary oral cancers with long-term use. Avoid extravasation. Embryo-fetal toxicity. Use effective contraception during and for 6 months after last dose. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

Caution with cyclosporine, phenobarbital, phenytoin, streptozocin, digoxin, myelosuppressants, others. Previous mediastinal irradiation, cyclophosphamide, other cardiotoxic drugs: monitor for cardiotoxicity and hepatotoxicity.

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand and foot syndrome, rash, neutropenia, thrombocytopenia, anemia; infusion reactions, cardiovascular events (eg, cardiomyopathy, CHF, acute LV failure), recall of skin reaction from prior radiation therapy, toxoplasmosis, urine discoloration (red/orange).

Elimination:

Hepatic.

Generic Availability:

YES

How Supplied:

Single-use vials (10mL, 25mL)—1

Indications for DOXIL:

AIDS-related Kaposi's sarcoma refractory to combination chemotherapy.

Adult:

Give by IV infusion at initial rate of 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur; may premedicate with antiemetics. 20mg/m2 once every 3 weeks. Hepatic dysfunction (serum bilirubin ≥1.2mg/dL), hand-foot syndrome, hematologic toxicity (esp. ANC, platelets), or stomatitis: reduce dose. Consider total anthracycline and anthracenedione doses and irradiation when calculating total cumulative dose. See full labeling.

Children:

Not established.

Warnings/Precautions:

Not substitutable on a mg/mg basis with other doxorubicin products. Cardiomyopathy (including left ventricular failure), acute infusion-related reactions, myelosuppression may occur. Have medications to treat infusion-related reactions and resuscitative equipment available. Hepatic impairment. Monitor blood (esp. CBC + platelets), hepatic (esp. SGOT/SGPT, alkaline phosphatase), and cardiac function (eg, MUGA, ECG). Monitor periodically for secondary oral cancers with long-term use. Avoid extravasation. Embryo-fetal toxicity. Use effective contraception during and for 6 months after last dose. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

Caution with cyclosporine, phenobarbital, phenytoin, streptozocin, digoxin, myelosuppressants, others. Previous mediastinal irradiation, cyclophosphamide, other cardiotoxic drugs: monitor for cardiotoxicity and hepatotoxicity.

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand and foot syndrome, rash, neutropenia, thrombocytopenia, anemia; infusion reactions, cardiovascular events (eg, cardiomyopathy, CHF, acute LV failure), recall of skin reaction from prior radiation therapy, toxoplasmosis, urine discoloration (red/orange).

Elimination:

Hepatic.

Generic Availability:

YES

How Supplied:

Single-use vials (10mL, 25mL)—1

Indications for DOXIL:

Multiple myeloma, in combination with bortezomib, in patients not previously treated with bortezomib and who have received at least one prior therapy.

Adult:

Give by IV infusion at initial rate of 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur; may premedicate with antiemetics. 30mg/m2 on day 4 of each cycle following bortezomib (see full labeling for bortezomib dose); may treat for up to 8 cycles. Hepatic dysfunction (serum bilirubin ≥1.2mg/dL), hand-foot syndrome, hematologic toxicity (esp. ANC, platelets), or stomatitis: reduce dose. Consider total anthracycline and anthracenedione doses and irradiation when calculating total cumulative dose. See full labeling.

Children:

Not established.

Warnings/Precautions:

Not substitutable on a mg/mg basis with other doxorubicin products. Cardiomyopathy (including left ventricular failure), acute infusion-related reactions, myelosuppression may occur. Have medications to treat infusion-related reactions and resuscitative equipment available. Hepatic impairment. Monitor blood (esp. CBC + platelets), hepatic (esp. SGOT/SGPT, alkaline phosphatase), and cardiac function (eg, MUGA, ECG). Monitor periodically for secondary oral cancers with long-term use. Avoid extravasation. Embryo-fetal toxicity. Use effective contraception during and for 6 months after last dose. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

Caution with cyclosporine, phenobarbital, phenytoin, streptozocin, digoxin, myelosuppressants, others. Previous mediastinal irradiation, cyclophosphamide, other cardiotoxic drugs: monitor for cardiotoxicity and hepatotoxicity.

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand and foot syndrome, rash, neutropenia, thrombocytopenia, anemia; infusion reactions, cardiovascular events (eg, cardiomyopathy, CHF, acute LV failure), recall of skin reaction from prior radiation therapy, toxoplasmosis, urine discoloration (red/orange).

Elimination:

Hepatic.

Generic Availability:

YES

How Supplied:

Single-use vials (10mL, 25mL)—1

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »